Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women

Clinical Cancer Research

Volumn 8, Issue 11, 2002, Pages 3324-3331

  Rathi, Asha ^a   Virmani, Arvind K ^a,b   Schorge, John O ^a,b   Elias, Keren J ^a,b   Maruyama, Riichiroh ^a   Minna, John D ^a   Mok, Samuel C ^c   Girard, Luc ^a   Fishman, David A ^d   Gazdar, Adi F ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; APC GENE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CLINICAL ARTICLE; DNA METHYLATION; E CADHERIN GENE; FAMILY HISTORY; FEMALE; GENE; GENE MUTATION; H1C1 GENE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; ONCOGENE; OVARY TUMOR; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RASSF1A GENE; AGAR GEL ELECTROPHORESIS; CELL CULTURE; DNA SEQUENCE; FAMILY HEALTH; GENETICS; METABOLISM; MUTATION; OVARY; RISK; TUMOR SUPPRESSOR GENE;

DNA; GLUTATHIONE TRANSFERASE;

DNA; DNA METHYLATION; ELECTROPHORESIS, AGAR GEL; FAMILY HEALTH; FEMALE; GENES, BRCA1; GLUTATHIONE TRANSFERASE; HUMANS; MUTATION; OVARIAN NEOPLASMS; OVARY; POLYMERASE CHAIN REACTION; RISK; SEQUENCE ANALYSIS, DNA; TUMOR CELLS, CULTURED;

EID: 0036847546     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Greenlee, R. T., Hill-Harmon, M. B., Murray, T., and Thun, M. Cancer statistics, 2001. CA Cancer J. Clin., 51: 15-36, 2001
2. Clark, T. G., Stewart, M. E., Altman, D. G., Gabra, H., and Smyth, J. F. A prognostic model for ovarian cancer. Br. J. Cancer, 85: 944-952, 2001
3. NIH-consensus conference. Ovarian cancer: Screening, treatment and follow-up. NIH-consensus development panel on ovarian cancer. JAMA, 273: 491-497, 1995
4. Ford, D., and Easton, D. F. The genetics of breast and ovarian cancer. Br. J. Cancer, 72: 805-812, 1995
5. Claus, E. B., Schildkraut, J. M., Thompson, W. D., and Risch, N. J. The genetic attributable risk of breast and ovarian cancer. Cancer (Phila.), 77: 2318-2324, 1996
6. Ries, L. A., Kosary, C. L., Hankey, B. F., Miller, B. A., and Edward, R. K. SEER Cancer Statistic Review 1973-1995. Bethesda, MD: National Cancer Institute, 1998
7. Boring, C. C., Squires, T. S., Tong, T., and Montgomery, S. Cancer statistics, 1994. CA Cancer J. Clin., 44: 7-26, 1994
8. Cliby, W., Ritland, S., Hartmann, L., Dodson, M., Hailing, K. C., Keeney, G., Podratz, K. C., and Jenkins, R. B. Human epithelial ovarian cancer allelotype. Cancer Res., 53: 2393-2398, 1993
9. Sato, T., Saito, H., Morita, R., Koi, S., Lee, J. H., and Nakamura, Y. Allelotype of human ovarian cancer. Cancer Res., 51: 5118-5122, 1991
10. Jones, P. A., and Laird, P. W. Cancer epigenetics comes of age. Nat. Genet., 21: 163-167, 1999
11. Warnecke, P. M., and Bestor, T. H. Cytosine methylation and human cancer. Curr. Opin. Oncol., 12: 68-73, 2000
12. Baylin, S. B., and Herman, J. G. DNA hypermethylation in tumorigenesis: Epigenetics joins genetics. Trends Genet., 16: 168-174, 2000
13. Esteller, M., and Herman, J. G. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J. Pathol., 196: 1-7, 2002
14. Costello, J. F., Fruhwald, M. C., Smiraglia, D. J., Rush, L. J., Robertson, G. P., Gao, X., Wright, F. A., Feramisco, J. D., Peltomaki, P., Lang, J. C., Schuller, D. E., Yu, L., Bloomfield, C. D., Caligiuri, M. A., Yates, A., Nishikawa, R., Su Huang, H., Petrelli, N. J., Zhang, X., O'Dorisio, M. S., Held, W. A., Cavenee, W. K., and Plass, C. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat. Genet., 24: 132-138, 2000
15. Cairns, P., Esteller, M., Herman, J. G., Schoenberg, M., Jeronimo, C., Sanchez-Cespedes, M., Chow, N. H., Grasso, M., Wu, L., Westra, W. B., and Sidransky, D. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin. Cancer Res., 7: 2727-2730, 2001
16. McCluskey, L. L., Chen, C., Delgadillo, E., Felix, J. C., Muderspach, L. I., and Dubeau, L. Differences in p16 gene methylation and expression in benign and malignant ovarian tumors. Gynecol. Oncol., 72: 87-92, 1999
17. Yoon, J. H., Dammann, R., and Pfeifer, G. P. Hypermethylation of the CpG island of the RASSFIA gene in ovarian and renal cell carcinomas. Int. J. Cancer, 94: 212-217, 2001
18. Esteller, M., Silva, J. M., Dominguez, G., Bonilla, F., Matias-Guiu, X., Lerma, E., Bussaglia, E., Prat, J., Harkes, I. C., Repasky, E. A., Gabrielson, E., Schutte, M., Baylin, S. B., and Herman, J. G. Promoter hypermethylation and BRCAI inactivation in sporadic breast and ovarian tumors. J. Natl. Cancer Inst., 92: 564-569, 2000
19. Strathdee, G., MacKean, M. J., Illand, M., and Brown, R. A role for methylation of the hMLH1 promoter in loss of hMLHI expression and drug resistance in ovarian cancer. Oncogene, 18: 2335-2341, 1999
20. Strathdee, G., Appleton, K., Illand, M., Millan, D. W., Sargent, J., Paul, J., and Brown, R. Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am. J. Pathol., 158: 1121-1127, 2001
21. Ahluwalia, A., Yan, P., Hurteau, J. A., Bigsby, R. M., Jung, S. H., Huang, T. H., and Nephew, K. P. DNA methylation and ovarian cancer. I. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization. Gynecol. Oncol., 82: 261-268, 2001
22. Jones, P. A., and Baylin, S. B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet., 3: 415-428, 2002
23. Pecorelli, S., Benedet, J. L., Creasman, W. T., and Shepherd, J. H. FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecol. Oncol. International Federation of Gynecology and Obstetrics. Int. J. Gynaecol. Obstet., 65: 243-249, 1999
24. Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D., and Baylin, S. B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA, 93: 9821-9826, 1996
25. Virmani, A. K., Rathi, A., Zochbauer-Muller, S., Sacchi, N., Fukuyama, Y., Bryant, D., Maitra, A., Heda, S., Fong, K. M., Thunnissen, F., Minna, J. D., and Gazdar, A. F. Promoter methylation and silencing of the retinoic acid receptor-β gene in lung carcinomas. J. Natl. Cancer Inst., 92: 1303-1307, 2000
26. Esteller, M., Corn, P. G., Urena, J. M., Gabrielson, E., Baylin, S. B., and Herman, J. G. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res., 58: 4515-4518, 1998
27. Burbee, D. G., Forgacs, E., Zochbauer-Muller, S., Shivakumar, L., Fong, K., Gao, B., Randle, D., Kondo, M., Virmani, A., Bader, S., Sekido, Y., Latif, F., Milchgrub, S., Toyooka, S., Gazdar, A. F., Lerman, M. I., Zabarovsky, E., White, M., and Minna, J. D. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J. Natl. Cancer Inst., 93: 691-699, 2001
28. Virmani, A. K., Rathi, A., Sathyanarayana, U. G., Padar, A., Huang, C. X., Cunnigham, H. T., Farinas, A. J., Milchgrub, S., Euhus, D. M., Gilcrease, M., Herman, J., Minna, J. D., and Gazdar, A. F. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. Clin. Cancer Res., 7: 1998-2004, 2001
29. Sato, M., Mori, Y., Sakurada, A., Fujimura, S., and Horii, A. The H-cadherin (CDH13) gene is inactivated in human lung cancer. Hum. Genet., 103: 96-101, 1998
30. Graff, J. R., Greenberg, V. E., Herman, J. G., Westra, W. H., Boghaert, E. R., Ain, K. B., Saji, M., Zeiger, M. A., Zimmer, S. G., and Baylin, S. B. Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle's cell, and poorly differentiated human thyroid carcinoma. Cancer Res., 58: 2063-2066, 1998
31. Dong, S. M., Kim, H. S., Rha, S. H., and Sidransky, D. Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin. Cancer Res., 7: 1982-1986, 2001
32. Baylin, S. B., Herman, J. G., Graff, J. R., Vertino, P. M., and Issa, J. P. Alterations in DNA methylation: A fundamental aspect of neoplasia. Adv. Cancer Res., 72: 141-196, 1998
33. Darai, E., Scoazec, J. Y., Walker-Combrouze, F., Mlika-Cabanne, N., Feldmann, G., Madelenat, P., and Potet, F. Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: A clinicopathologic study of 60 cases. Hum. Pathol., 28: 922-928, 1997
34. Nass, S. J., Herman, J. G., Gabrielson, E., Iversen, P. W., Parl, F. F., Davidson, N. E., and Graff, J. R. Aberrant methylation of the estrogen receptor and E-cadherin 5′ CpG islands increases with malignant progression in human breast cancer. Cancer Res., 60: 4346-4348, 2000
35. Dammann, R., Yang, G., and Pfeifer, G. P. Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res., 61: 3105-3109, 2001
36. Fujii, H., Biel, M. A., Zhou, W., Weitzman, S. A., Baylin, S. B., and Gabrielson, E. Methylation of the HIC-1 candidate tumor suppressor gene in human breast cancer. Oncogene. 16: 2159-2164, 1998
37. Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., and Sidransky, D. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med., 1: 686-692, 1995
38. Virmani, A. K., Muller, C., Rathi, A., Zoechbauer-Mueller, S., Mathis, M., and Gazdar, A. F. Aberrant methylation during cervical carcinogenesis. Clin. Cancer Res., 7: 584-589, 2001
39. Shih, Y. C., Kerr, J., Liu, J., Hurst, T., Khoo, S. K., Ward, B., Wainwright, B., and Chenevix-Trench, G. Rare mutations and no hypermethylation at the CDKN2A locus in epithelial ovarian tumours. Int. J. Cancer, 70: 508-511, 1997
40. Toyooka, K. O., Toyooka, S., Virmani, A. K., Sathyanarayana, U. G., Euhus, D. M., Gilcrease, M., Minna, J. D., and Gazdar, A. F. Loss of expression and aberrant methylation of the CDH 13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res., 61: 4556-4560, 2001
41. Kawakami, M., Staub, J., Cliby, W., Hartmann, L., Smith, D. I., and Shridhar, V. Involvement of H-cadherin (CDH13) on 16q in the region of frequent deletion in ovarian cancer. Int. J. Oncol., 15: 715-720, 1999
42. Bianco, T., Chenevix-Trench, G., Walsh, D. C., Cooper, J. E., and Dobrovic, A. Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer. Carcinogenesis (Lond.), 21: 147-151, 2000
43. Catteau, A., Harris, W. H., Xu, C. F., and Solomon, E. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: Correlation with disease characteristics. Oncogene, 18: 1957-1965, 1999
44. Baldwin, R. L., Nemeth, E., Tran, H., Shvartsman, H., Cass, I., Narod, S., and Karlan, B. Y. BRCA1 promoter region hypermethylation in ovarian carcinoma: A population-based study. Cancer Res., 60: 5329-5333, 2000
45. Gras, E., Cortes, J., Diez, O., Alonso, C., Matias-Guiu, X., Baiget, M., and Prat, J. Loss of heterozygosity on chromosome 13q12-q14. BRCA-2 mutations and lack of BRCA-2 promoter hypermethylation in sporadic epithelial ovarian tumors. Cancer (Phila.), 92: 787-795, 2001
46. Boyd, J., Sonoda, Y., Federici, M. G., Bogomolniy, F., Rhei, E., Maresco, D. L., Saigo, P. E., Almadrones, L. A., Barakat, R. R., Brown, C. L., Chi, D. S., Curtin, J. P., Poynor, E. A., and Hoskins, W. J. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA, 283: 2260-2265, 2000
47. Rubin, S. C., Benjamin, I., Behbakht, K., Takahashi, H., Morgan, M. A., LiVolsi, V. A., Berchuck, A., Muto, M. G., Garber, J. E., Weber, B. L., Lynch, H. T., and Boyd, J. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N. Engl. J. Med., 335: 1413-1416, 1996
48. Scully, R. E. Pathology of ovarian cancer precursors. J. Cell. Biochem., 23(Suppl.): 208-218, 1995
49. Salazar, H., Godwin, A. K., Daly, M. B., Laub, P. B., Hogan, W. M., Rosenblum, N., Boente, M. P., Lynch, H. T., and Hamilton, T. C. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J. Natl. Cancer Inst., 88: 1810-1820, 1996
50. Casey, M. J., Bewtra, C., Hoehne, L. L., Tatpati, A. D., Lynch, H. T., and Watson, P. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds. Gynecol. Oncol., 78: 278-287, 2000
51. Barakat, R. R., Federici, M. G., Saigo, P. E., Robson, M. E., Offit, K., and Boyd, J. Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes. Cancer (Phila.), 89: 383-390, 2000
52. Kaneto, H., Sasaki, S., Yamamoto, H., Itoh, F., Toyota, M., Suzuki, H., Ozeki, I., Iwata, N., Ohmura, T., Satoh, T., Karino, Y., Toyota, J., Satoh, M., Endo, T., Omata, M., and Imai, K. Detection of hypermethylation of the p16(INK4A) gene promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C virus. Gut, 48: 372-377, 2001
53. Issa, J. P. CpG-island methylation in aging and cancer. Curt. Top. Microbiol. Immunol., 249: 101-118, 2000
54. Ueki, T., Walter, K. M., Skinner, H., Jaffee, E., Hruban, R. H., and Goggins, M. Aberrant CpG island methylation in cancer cell lines arises in the primary cancers from which they were derived. Oncogene, 21: 2114-2117, 2002